South San Francisco

23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.

Concerns have been raised about how 23andMe could potentially handle customer information due to the company’s uncertain future.